Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — DNB Nordic Healthcare Conference 2020
18 slides from Bioinvent International Ab's conference presentation, Dec 15, 2020
Slide 1: DNB Nordic Healthcare Conference
DNB NORDIC HEALTHCARE CONFERENCE December 15th 2020
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: Company Snapshot
COMPANY SNAPSHOT LEADING IMMUNO-ONCOLOGY ANTIBODY PLATFORM • Advancing Cancer Immunotherapy by overcoming tumor resistance ✓ • Lead product, BI-1206, currently in Phase I/II for relapsed or refractory indolent Non-Hodgkin Lymphoma (iNHL) patients with early results from Phase I open label study expe
Slide 4: F.I.R.S.T. Phenotypic Discovery of New Oncology Targets and Antibodies
F.I.R.S.T™ PHENOTYPIC DISCOVERY OF NEW ONCOLOGY TARGETS AND ANTIBODIES 4 │
Slide 5: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS Indication Program Discovery Preclinical Phase I Phase II Partner Target: FcγRIIB iNHL (MCL, MZL, iFL) BI-1206/Rituximab Solid tumors BI-1206/Pembrolizumab Solid tumors BI-1607 2021 Target: Tumor associated regulatory T cells (Tregs) Solid tumors BT-001 -α-CTLA4 Mab
Slide 6: FcγRIIB – A Single Inhibitory Antibody Checkpoint
FcγRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY IN BOTH LIQUID AND SOLID TUMORS Antibody Checkpoints T-Cell Checkpoints Activates Innate Immune System Adaptive immune System Part of the immune system that kills tumor cells, Part of the immune system that eliminates t
Slide 7: BI-1206 in Non-Hodgkin Lymphoma Enhances Activity of Anti-CD20 mAb
BI-1206 IN NON-HODGKIN LYMPHOMA ENHANCES THE ACTIVITY OF ANTI-CD20 MAB • Rituximab (Roche’s Rituxan® or The immune cell fails to attack the tumor cell Mabthera®) is a monoclonal antibody that kills malignant B cells RITUXIMAB ALONE by binding to CD20 on the cell surface • The FcgRIIB-receptor functi
Slide 8: BI-1206 in Non-Hodgkin Lymphoma: Dual Impact on B Cells
BI-1206 IN NON-HODGKIN LYMPHOMA: DUAL IMPACT ON B CELLS - Bi-1206 blocks rituximab internalization and improves its anti-tumor activity Human CD20 FcγR2B double transgenic mice Humanized model of relapsed / refractory CLL B cell depletion in vivo BOOSTING RITUXIMAB’S EFFECT OVERCOMING RESISTANCE % o
Slide 9: BI-1206 in Non-Hodgkin Lymphoma: Value Proposition – Key Segments & Value Drivers
BI-1206 IN NON-HODGKIN LYMPHOMA: VALUE PROPOSTION – KEY SEGMENTS & VALUE DRIVERS KEY SUB-SEGMENTS OF NON-HODGKIN LYMPHOMA (NHL) BI-1206 value drivers ▪ Compelling scientific rationale in α-CD20 refractory B-cell lymphoma ▪ Chemo-free regimen MZLMZL MCLMCL USD ▪ Favorable safety profile ▪ Scalability
Slide 10: BI-1206 in Non-Hodgkin Lymphoma: Phase I/IIa Study
BI-1206 IN NON-HODGKIN LYMPHOMA: PHASE I/IIA STUDY STUDY OVERVIEW Current phase Start: Sep 2018 Part A Part B H2 2020 BI-1206 + RTX1 BI-1206 + RTX1 (375 mg/m2) (375 mg/m2) Patients with EARLY PHASE relapsed or 3+3 dose escalation Expansion phase I RESULTS refractory iNHL (n=9-12) IIa (n=12) (Expecte
Slide 11: Promising Preliminary Data from Phase I/IIa Study
BI-1206 IN NON-HODGKIN LYMPHOMA: PROMISING PRELIMINARY DATA FROM PHASE I/IIA STUDY • Preliminary data shows early signs of efficacy – In the 30 mg cohort: • 1 patient with FL remained on treatment for the full maintenance period (1 year) • 1 patient with blastoid Mantle Cell lymphoma, showed complet
Slide 12: BI-1206 Possesses Substantial Indication Growth Potential
BI-1206 POSSESSES SUBSTANTIAL INDICATION GROWTH POTENTIAL ESTABLISHING PROOF OF CONCEPT IN CERTAIN INDICATIONS CAN LEAD TO RAPID GROWTH IN TOTAL ADDRESSABLE MARKET Autoimmune diseases Other solid tumors NSCLC Metastatic melanoma NHL iNHL 12 │
Slide 13: BI-1206 Potential Mechanisms of Action
BI-1206 POTENTIAL MECHANISMS OF ACTION - REDUCING aPD-1-MEDIATED CD8+ T CELL DEPLETION AND MAXIMIZING PD-1/PDL1 BLOCKADE 13 │ Confidential
Slide 14: BI-1206 in Solid Tumors: Phase I/IIa Study with Merck
BI-1206 IN SOLID TUMORS: PHASE I/IIA STUDY WITH MERCK STUDY OVERVIEW Current phase Start: Q1 2020 Part A Part B H2 2021 Patients with BI-1206 + EARLY If successful, the potential BI-1206 + solid tumors addressable market could be pembrolizumab pembrolizumab PHASE I relapsed or (200mg) (200mg) sizabl
Slide 15: Targeting Tregs and TAMs to Mitigate Immune Suppression
TARGETING TREGS AND TAMS TO MITIGATE IMMUNE SUPPRESSION ▪ Regulatory T cells (Tregs) can Developing antibodies that act on Tregs via novel or validated targets substantially inhibit immune 1 2 3 TARGETING TREGS responses, enabling tumor cells to escape detection ▪ BioInvent is utilizing its F.I.R.S.
Slide 16: BT-001: mAbs + Oncolytic Virus to Target Solid Tumors
BT-001: MABS + ONCOLYTIC VIRUS TO TARGET SOLID TUMORS – 50/50 partnership with transgene to develop next generation oncolytic viruses mAbs and oncolytic virus attack the solid tumor together ABOUT THE COLLABORATION BioInvent’s CTLA-4 mAb ▪ BioInvent and Transgene collaborate to co- develop oncolytic
Slide 17: Proprietary Manufacturing Platform Since 1988
PROPRIETARY MANUFACTURING PLATFORM SINCE 1988 BioInvent has ample experience with in-house production of antibodies ensuring that no delays will occur when scaling up production to meet the demand for the various clinical trials • Supports fast and flexible production of proprietary programs • Appro
Slide 18: Upcoming News Flow
UPCOMING NEWS FLOW ✓ BI-1206 / pembrolizumab research and supply agreement with Merck (MSD) ✓ Pfizer selects second target for development from TAMs program collaboration Q4 2019 ✓ BioInvent / Transgene announce promising preclinical data for BT-001 in solid tumors ✓ Promising preclinical data BI-12
BioInvent International — DNB Nordic Healthcare Conference 2020 on 6ix